143 related articles for article (PubMed ID: 38462352)
1. [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer].
Dong YT; Guan J; Yang BY; Yierfulati G; Xue Y; Chen XJ
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):729-735. PubMed ID: 38462352
[No Abstract] [Full Text] [Related]
2. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
3. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
5. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
[TBL] [Abstract][Full Text] [Related]
7. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
8. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.
Shan W; Wang C; Zhang Z; Gu C; Ning C; Luo X; Zhou Q; Chen X
J Gynecol Oncol; 2014 Jul; 25(3):214-20. PubMed ID: 25045434
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
Xu Z; Yang B; Shan W; Liao J; Shao W; Wu P; Zhou S; Ning C; Luo X; Zhu Q; Zhang H; Ma F; Guan J; Chen X
Gynecol Oncol; 2023 Jul; 174():133-141. PubMed ID: 37182434
[TBL] [Abstract][Full Text] [Related]
10. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
11. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
[TBL] [Abstract][Full Text] [Related]
12. Metformin for endometrial hyperplasia.
Clement NS; Oliver TR; Shiwani H; Sanner JR; Mulvaney CA; Atiomo W
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012214. PubMed ID: 29077194
[TBL] [Abstract][Full Text] [Related]
13. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Shao F; Li Y; Zhao Y
Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
[TBL] [Abstract][Full Text] [Related]
14. Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma.
Jing CY; Li SN; Shan BE; Zhang W; Tian WJ; Ren YL; Wang HY
Clin Med Insights Oncol; 2022; 16():11795549221110522. PubMed ID: 35875417
[TBL] [Abstract][Full Text] [Related]
15. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
16. Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Ushijima K; Tsuda N; Yamagami W; Mitsuhashi A; Mikami M; Yaegashi N; Enomoto T
J Gynecol Oncol; 2023 May; 34(3):e38. PubMed ID: 36659833
[TBL] [Abstract][Full Text] [Related]
17. The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial.
Tehranian A; Ghahghaei-Nezamabadi A; Arab M; Khalagi K; Aghajani R; Sadeghi S
J Gynecol Obstet Hum Reprod; 2021 Jun; 50(6):101863. PubMed ID: 32652300
[TBL] [Abstract][Full Text] [Related]
18. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments.
Yin J; Ma S; Shan Y; Wang Y; Li Y; Jin Y; Pan L
Cancer Prev Res (Phila); 2020 Apr; 13(4):403-410. PubMed ID: 32015095
[TBL] [Abstract][Full Text] [Related]
19. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
20. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]